CD8A and neoplasm: As this result is seemingly contradictory, we hypothesized that KO MDSCs co-injected with B16F10-Fluc tumor cells initially do not hamper CD8+ T-cells as much as WT MDSCs do, enabling these CD8+ T-cells to keep the tumor growth under control during the first days of tumor growth (Figure 4b), and likely pressuring B16F10-Fluc tumor cells to adopt mechanisms to paralyze these CD8+ T-cells.